Macquarie Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Macquarie Group’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-600	Closed	-$9K	–	2489
2017 Q4	$9K	Buy	+600	New	+$8.02K	﹤0.01%	2293

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Macquarie Group's STML Position: Q1 2018 in Review

Macquarie Group sold out of Stemline Therapeutics, Inc. (STML) in Q1 2018, closing a stake of 600 shares — an estimated $9K sold.

Macquarie Group first reported a position in STML in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 82 funds tracked by Wall St. Rank hold STML as of Q1 2018.

Macquarie Group reported no remaining Stemline Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 600 Stemline Therapeutics, Inc. shares in Q1 2018, an estimated $9K.
Macquarie Group first reported a position in Stemline Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Macquarie Group's Stemline Therapeutics, Inc. position peaked at $9K in Q4 2017.
82 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.